Figure 3.

Programmed death-1 (PD-1) blockade enhances antitumor responses to cyclic diadenyl monophosphate (CDA). (A, B) B6 mice with established Lewis lung carcinoma (LLC) tumors were treated with CDA with or without anti-PD-1 monoclonal antibodies (mAbs) to disrupt immune checkpoints (ICPs) (see ‘Methods’ section). Tumor volumes (A) and mouse survival (B) were assessed until experimental end points (day 60). At end points mice were examined to assess tumor clearance or relapse. Data (mean±SEM) were analyzed using two-way analysis of variance with Bonferroni’s multiple comparisons test for each time point (A) or the log-rank test (B), n=7–9. *P<0.05, ***p<0.001, ****p<0.0001 (vs vehicle (Vh)); ##p<0.01, ###p<0.001 (vs CDA monotherapy); &&& p<0.001 (vs anti-PD1 monotherapy).